DOI:

Transcatheter aortic valve implantation for pure severe native aortic regurgitation

Roy D.1, Schaefer U.2, Guetta V.3, Hildick-Smith D.4, Moellman H.5, Dumonteil N.6, Modine T.7, Bosmans J.8, Moat N.9, Linke A.10, Morris C.11, Petronio A.S.12, Champagnac D.13, Medvedofsky D.3, Patterson T.9, Woitek F.8, Jahagiri M.1, Laborde J.C.1, Brecker S.1

Treatment and consequences of regurgitation during transcatheter valve therapies

Transcatheter aortic valve implantation for pure severe native aortic regurgitation

Aims: Transcatheter aortic valve implantation (TAVI) is an established treatment for patients with severe aortic valve stenosis and prohibitive or high surgical risk. There is limited data and experience for TAVI in the treatment of patients with pure severe native valve aortic regurgitation. We aimed to evaluate the off-label treatment of pure native aortic regurgitation (NAR) with TAVI for patients with prohibitive surgical risk by examining the procedural and clinical results from a retrospective worldwide registry of patients with NAR treated with TAVI.

Methods and results: Data on baseline patient characteristics, device and procedural parameters, echocardiographic parameters and outcomes up to June 2012 were collected retrospectively in a uniform spreadsheet from 14 centres that have performed TAVI for pure NAR. A total of 43 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, MN, USA) in 14 centres (mean age 75.3±8.8 years, 53% female, mean logistic EuroSCORE 26.9±17.9%, mean STS score of 10.2±5.3%, n=35 transfemoral, n=4 subclavian, n=3 direct aortic, n=1 carotid). The mean annulus size was 23.7±2.1 mm and the 29 mm prosthesis was most commonly used (n=21 29 mm, n=14 26 mm, n=1 31 mm). Implantation was successful in 42 patients (97.7%) and 8 (18.6%) patients required a second valve during the index procedure for residual aortic regurgitation. In all cases where a second valve was needed, annular calcification was absent (p=0.014). Post-procedure aortic regurgitation ≤ grade I was present in 34 patients (79.1%). All-cause mortality at 30 days was 9.3% (4 patients) and the incidence of major strokes was 4.7% at 30 days. At 12 months, the all-cause mortality was 21.4% (6/28 patients) with a cardiovascular mortality of 10.7% (3 patients).

Conclusions: This represents the first registry analysis of patients being treated with TAVI for the indication of pure severe NAR. TAVI for severe NAR is feasible and can be an effective treatment for patients with prohibitive surgical risk.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00045 Sep 2, 2024
Severe aortic regurgitation: the limits of TAVI
Delgado V and Peláez E
free

Original Research

10.4244/EIJ-D-24-00339 Sep 2, 2024
Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation
Le Ruz R et al

Editorial

10.4244/EIJ-E-23-00039 Sep 18, 2023
Transcatheter aortic valve implantation: the shape matters
Kim W and Holzamer A
free

10.4244/EIJV9SSA11 Sep 15, 2013
Native aortic valve regurgitation: transcatheter therapeutic options
Roy D et al
free

CLINICAL RESEARCH

10.4244/EIJV10I6A127 Oct 20, 2014
CoreValve implantation for severe aortic regurgitation: a multicentre registry
Testa L et al
free

10.4244/EIJV7I1A25 May 17, 2011
How should I treat acute valve regurgitation?
Schultz C et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved